热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响*

doi:10.3969/j.issn.1672-5069.2020.02.018

摘要/Abstract

摘要： 目的非酒精性脂肪性肝病(NAFLD)是慢性肝病中最常见的一种,与代谢异常和氧化应激相关。本研究旨在评估热量限制饮食对NAFLD患者胰岛素抵抗、血脂谱和氧化应激指标的影响。方法 2018年1月～2019年1月我院诊治的NAFLD患者124例,将符合纳入标准的NAFLD患者随机分为A组和B组,每组62例。A组患者在保证蛋白质、基本维生素和微量元素供给的前提下,每日热量摄入控制在1200～1500 kcal,B组自行设计饮食控制,观察12周。结果治疗前,两组空腹血糖(FPG)、胰岛素、胰岛素抵抗指标(HOMA-IR)、胰岛B细胞功能(HOMA-B)和胰岛素敏感性检测指标(QUICKI)无显著性差异(P>0.05),经过12周饮食控制治疗后,A组HOMA-IR为(3.5±2.0),显著低于B组[(4.7±2.2),P<0.05],QUICKI为(0.3±0.1),显著高于B组[(0.2±0.2),P<0.05],而两组FPG、胰岛素水平和HOMA-B均无显著性统计学差异(P>0.05);治疗前,两组血低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、甘油三酯(TG)和总胆固醇(TC)水平无显著性差异(P>0.05),在12周观察期末,A组血LDL为(120.7±23.7)mg/dL,显著低于B组[(149.0±33.4)mg/dL,P<0.05],TC为(197.6±40.7)mg/dL,显著低于B组[(230.5±42.8)mg/dL,P<0.05],TG为(176.2±75.0)mg/dL,显著低于B组[(186.4±63.7)mg/dL,P<0.05],而血HDL水平为(43.5±7.4)mg/dL,显著高于B组([(40.9±8.2)mg/dL,P<0.05];治疗前,A组和B组血清MDA水平分别为(60.6±35.2)μmol/L和(60.7±36.2)μmol/L,无显著性差异(P>0.05),而在12周观察期末,A组为(55.5±35.8)μmol/L,显著低于B组[(60.3±34.3)μmol/L,P<0.05]。结论采取热量限制饮食可有效改善NAFLD患者胰岛素抵抗、血脂谱和氧化应激指标,值得在临床上进行广泛的验证。

关键词: 非酒精性脂肪性肝病, 热量限制饮食, 胰岛素抵抗, 总胆固醇, 甘油三酯, 氧化应激

Abstract: Objective Non-alcoholic fatty liver diseases (NAFLD) is the most common type of chronic liver disease all over the world, which is related to metabolic abnormalities and oxidative stress. The purpose of this study was to assess the effects of calorie restriction diet on insulin resistance, lipid profile and oxidative stress index in patients with NAFLD. Methods 124 patients with NAFLD were recruited in our hospital From January 2018 through January 2019, and were randomly divided into group A and group B, with 62 in each. The daily calorie intake in groupA was controlled at 1200～1500 kcal.d^-1 on the premise of ensuring protein, basic vitamin and trace element intake, the patients in group B designed their own diets forthemselves. The study lasted for 12 weeks. Results At presentation, there was no significant differences in fasting blood glucose (FPG), insulin, insulin resistance index (HOMA-IR), islet B cell function (HOMA-B) and insulin sensitivity detection index (QUICKI) between the two groups (P>0.05), while at the end of 12 weeks of observation, the HOMA-IR in group A was (3.5±2.0) , significantly lower than [(4.7±2.2), P < 0.05) in group B, and the QUICKI was (0.3±0.1) , significantly higher than [(0.2±0.2), P<0.05] in group B, and there were no significant differences (P>0.05) as respect to FPG, insulin and HOMA-B in the two groups; before treatment, there was no significant difference in blood lipid profile, such as blood low density lipoprotein (LDL), high density lipoprotein (HDL), triglyceride (TG) and total cholesterol (TC) between the two groups (P>0.05), and at the end of 12 week observation, the blood LDL level in group A was (120.7±23.7) mg/dl, significantly lower than [(149.0±33.4) mg/dl, P<0.05] in group B, blood TC level was (197.6±40.7) mg/dl, significantly lower than [(230.5±42.8) mg/dl, P<0.05], and blood TG level was (176.2±75.0) mg/dl, significantly lower than [(186.4±63.7) mg/dl, P<0.05], while blood HDL level was (43.5±7.4) mg/dl, significantly higher than [(40.9±8.2) mg/dl, P< 0.05) in group B; there was no significant difference in serum malondialdehyde (MDA) between the two groups [(60.6±35.2) μ mol/l vs. (60.7±36.2) μmol/l, P > 0.05], while at the end of 12 week observation, serum MDA level in group A was [(55.5±35.8) μmol/l, significantly lower than [(60.3±34.3) μmol/l, P<0.05] in group B. Conclusion The application of calorie restriction diets might effectively improve insulin resistance, blood lipid profile and oxidative stress in patients with NAFLD, which is worth further study in multi-central clinical practice.

Key words: Nonalcoholic fatty liver disease, Calorie-restricted diets, Insulin resistance, Total cholesterol, Triglyceride, Oxidative stress

任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.

Ren Guoliang, Li Liansheng, Liu Gang, et al. Improvement of insulin resistance, lipid profile and oxidative stress index by calorie restriction diet in patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2020, 23(2): 219-222.

参考文献

[1] Charlton MR,Burns JM,Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology,2011,141(4):1249-1253.
[2] Perumpail BJ, Khan MA, Yoo ER, et al. Clinicalepidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017, 23(47):8263-8276.
[3] Han J, Wang Y, Yuan Z, et al. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study. Medicine (Baltimore),2019,98(11):e14896.
[4] Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol,2011,17(2):271-272.
[5] Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev, 2010, 15(4):313-28.
[6] Wang Y. Molecular links between caloric restriction and Sir2/SIRT1 activation. Diabetes Metab J, 2014, 38(5):321-329.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[8] Finer N. Low-calorie diets and sustained weight loss. Obes Res, 2001, 9(Suppl 4):S290–S294.
[9] El-Sayed MI. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. J Ethnopharmacol, 2011, 137(1):643-651.
[10] Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology, 2015, 61:1205–1215.
[11] Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut, 2011, 60:1278–1283.
[12] Lam YY, Peterson CM, Ravussin E. Resveratrol vs. calorie restriction:data from rodents to humans. Exp Gerontol, 2013, 48:1018–1024.
[13] Dali-Youcef N, Lagouge M, Froelich S, et al. Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med, 2007, 39:335–345.
[14] Kelly G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. AlternMed Rev, 2010, 15:245–263.
[15] Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit Basic Res, 2011, 17:HY5–HY9.
[16] Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev, 2012, 92:1479–1514.
[17] Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305:390–392.
[18] Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med, 2007, 4: e76.
[19] Mariani S, Fiore D, Basciani S, et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine, 2014,45:1–6.
[20] Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol, 2018,18(1):165.

热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*

Improvement of insulin resistance, lipid profile and oxidative stress index by calorie restriction diet in patients with non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿. 非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 163-166.
[2]	姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.
[3]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[4]	叶晓贤, 杨丽, 雷丽. 血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 199-202.
[5]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[6]	刘继国, 窦翠云, 程广玲. NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*[J]. 实用肝脏病杂志, 2020, 23(2): 207-210.
[7]	曾震军, 李墨航. 血清学指标和脂肪肝指数诊断非酒精性脂肪性肝病价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 211-214.
[8]	王丽娟, 朱兵兵, 胡敏华, 杨丽, 石莉红, 胡健薇. 匹伐他汀与阿托伐他汀治疗非酒精性脂肪性肝病患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(2): 215-218.
[9]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[10]	宁宝烁, 李异玲. PNPLA3对肝细胞和肝癌细胞脂质代谢的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 300-304.
[11]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[12]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[13]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[14]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[15]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.